Home >  News >  Industry >  Pharma News >  Centre to introduce...

Centre to introduce research linked incentive scheme to cover RnD costs for biotech products: DCGI Dr V G Somani

Underscoring the importance of policy reforms, innovation, and research and development, he said the government has taken several initiatives to aid innovative research and establish appropriate ecosystems.

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-01-21 05:53 GMT   |   Update On 2024-03-23 11:52 GMT
Advertisement

Nagpur: The Centre is all set to introduce a research-linked incentive programme shaped on the lines of the production linked incentive (PLI) scheme to boost research and development of biotech products in the country, said Drugs Controller General of India Dr V G Somani on Friday. PLI scheme aims to give companies incentives on incremental sales from products manufactured in domestic units.

Somani was speaking on the first day of the 72nd Indian Pharmaceutical Congress in Nagpur. The three-day event will cover various issues related to the pharmaceutical industry, academia and community pharmacy and will be attended by delegates from India and abroad.
Advertisement
The accomplishments of the Indian pharmaceutical sector during the COVID years were a huge boon for society, said Somani, who heads India's apex drug regulatory agency Central Drugs Standard Control Organization (CDSCO).
"Firstly, the urgency to identify the virus (coronavirus) and secondly to develop vaccine, medicines and diagnostics for COVID-19 was not an ordinary challenge. But, with the encouragement from Prime Minister Narendra Modi, the Indian pharmaceutical industry accepted this challenge and successfully developed the vaccine that not only saved millions of lives in India but also in several other parts of the globe," said Somani.
Underscoring the importance of policy reforms, innovation, and research and development, he said the government has taken several initiatives to aid innovative research and establish appropriate ecosystems.
To enhance the capabilities of the domestic pharma industry and help it establish itself in the global market, Somani said, the Centre is "all set" to introduce a research-linked incentive (RLI) scheme shaped on the lines of the PLI programme to cover "R&D costs for biotech products".
Somani said the pharma industry has experienced numerous regulatory developments and several pharmaceutical companies are rethinking their regulatory approval and drug development strategies.
"Introduction of new Indian Pharmacopoeia 2022 and several amendments in rules for drugs and medical devices have been done to establish a dynamic pathway for ensuring patient safety while encouraging the growth of the sector," he said.

Read also: India targeting global arena with high value pharma med-tech products, says Mansukh Mandaviya

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Delhi HC Restrains Use of CALDIMUST Trademark Deceptively Similar to Mankind's CALCIMUST

Advisory issued to all allopathic drug manufacturers over risky solvents: Arti Singh Rao

Achin Gupta to succeed Umang Vohra as Cipla MD, GCEO effective April 1

No More Offline Filings: CDSCO Mandates Submission of Post-Approval Changes for Cell and Gene Therapy Trial via SUGAM Portal

Tourmaline becomes indirect wholly owned subsidiary of Novartis

Rs 2 Crore Medicine Scam Rocks Puducherry: Ex-Health Officials, Pharma Dealers Among 6 Held

Zydus Lifesciences Told To Revise PMS Study For Tofacitinib ER Tablets

GSK, Empirico collaborate for oligonucleotide candidate to treat respiratory diseases